secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0001437749-24-035040
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity Therapeutics reports Q3 net loss $12.2M; cash $18.5M; Phase 2 stenoparib patients exceed one year on treatment
--------------------------------------------------------------------------------

- Net loss $12.2M vs $5.6M YoY; includes $9.7M non-cash intangible impairment charge.
- Cash and equivalents $18.5M at Sept 30, 2024, up from $0.2M at Dec 31, 2023; runway into 2026.
- Phase 2 stenoparib trial: two ovarian cancer patients exceeded one year on treatment.
- Appointed Alexander Epshinsky as CFO; Jeremy Graff as President/Chief Development Officer; Jose Iglesias as Consultant CMO.
- Regained NASDAQ compliance; European patent granted for stenoparib DRP companion diagnostic.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/0001437749-24-035040-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000143774924035040/allr20241010c_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-035040

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer